Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?
Pharmaceutical Technology
FEBRUARY 18, 2023
Gevokizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase I program in Metastatic Renal Cell Carcinoma. XOMA 052 is a potent human engineered IgG2 monoclonal antibody, binds to IL-1 beta, a pro-inflammatory cytokine.
Let's personalize your content